Dayvigo (Lemborexant) Off-Label Use in Adolescents Ages 12 to 17

What Is Lemborexant and Why Is It Prescribed Off-Label in Teenagers?

Lemborexant blocks both orexin-1 and orexin-2 receptors in the hypothalamus, suppressing the wake-promoting signal that keeps patients aroused at sleep onset and during the night. The FDA approved it in December 2019 for chronic insomnia disorder in adults, based on the SUNRISE-1 and SUNRISE-2 phase 3 trials [1][2]. No pediatric indication exists.

Off-label prescribing is legal and common in the United States. The FDA estimates that roughly 21 percent of all outpatient prescriptions are written off-label, and that proportion rises substantially in pediatric and adolescent populations [3]. Adolescent insomnia is a recognized clinical problem: the American Academy of Sleep Medicine defines chronic insomnia as difficulty initiating or maintaining sleep at least three nights per week for three or more months, with associated daytime impairment [4]. Prevalence estimates in teenagers range from 10 to 23 percent depending on diagnostic criteria used [5].

Orexin signaling is active in adolescent brains. Cerebrospinal fluid orexin-A levels in children and adolescents with narcolepsy type 1 are deficient by the same threshold used in adults (below 110 pg/mL), confirming the orexin system is functionally mature in this age range [6]. That biological continuity is one reason clinicians extrapolate adult DORA data to teenagers, even absent a dedicated trial.

The Regulatory Gap

The FDA's 2019 approval letter for lemborexant did not include a Pediatric Research Equity Act (PREA) waiver or deferral for the 12-to-17 age group, meaning Eisai was not required to generate adolescent data before approval [7]. That gap leaves clinicians without label guidance on dose, safety monitoring, or contraindications specific to this population.

How Off-Label Prescribing Decisions Are Made

Physicians typically rely on three inputs when writing off-label sleep prescriptions for adolescents: pharmacokinetic extrapolation from adult studies, case series or registry data, and expert consensus statements. For lemborexant, the only strong data set available is from the SUNRISE program in adults, which enrolled participants 18 and older [1][2].

Pharmacokinetics in Adolescents: What Adult Data Can and Cannot Tell Us

Adult pharmacokinetic parameters for lemborexant are well characterized. Peak plasma concentration (Tmax) occurs at approximately 1 to 3 hours after a 10 mg dose, with a mean elimination half-life of 17.4 hours [8]. The drug is 94 percent protein-bound and undergoes primary hepatic metabolism via CYP3A4 [8].

Body Weight and Exposure

Population pharmacokinetic modeling from the SUNRISE trials found that body weight influenced lemborexant exposure. Lighter adults (below 55 kg) showed higher area under the curve (AUC) values compared with heavier adults [8]. Adolescents between 12 and 17 vary enormously in weight, from roughly 40 kg in early puberty to adult-range weights by late adolescence. This weight variability suggests exposure could differ substantially from adult reference ranges, although no adolescent-specific PK study has been conducted.

CYP3A4 Maturation

CYP3A4 enzymatic activity in adolescents aged 12 to 17 is generally equivalent to adult activity, unlike in neonates or young children where CYP3A4 is substantially reduced [9]. That developmental similarity supports the position that adult dosing guidance is at least approximately applicable for older adolescents, though it does not substitute for prospective adolescent PK data.

CNS Development Considerations

The adolescent prefrontal cortex continues myelinating into the mid-twenties [10]. Orexin receptors are expressed throughout corticolimbic circuits involved in emotional regulation and executive function. Prolonged OX1R and OX2R blockade during active cortical development has not been studied. This theoretical concern is not unique to lemborexant. It applies to all sedative-hypnotics in this age range and is one reason the FDA has historically required pediatric safety studies before granting pediatric indications for central nervous system drugs [7].

SUNRISE Trial Data: Efficacy Evidence Clinicians Extrapolate From

SUNRISE-1 Design and Results

SUNRISE-1 was a randomized, double-blind, placebo-controlled trial (N=1,006) comparing lemborexant 5 mg, lemborexant 10 mg, and placebo over 30 nights in adults with chronic insomnia disorder [1]. The primary endpoints were subjective sleep onset latency (sSOL) and subjective sleep efficiency (sSE). Lemborexant 10 mg reduced sSOL by a mean of 18.0 minutes versus 8.9 minutes for placebo at month 1 (P<0.001) [1]. Sleep efficiency improved by 9.9 percentage points on lemborexant 10 mg versus 4.7 percentage points on placebo (P<0.001) [1].

SUNRISE-2 Long-Term Safety

SUNRISE-2 extended follow-up to 12 months in adults (N=900) and found no evidence of rebound insomnia or dependence on abrupt discontinuation [2]. Somnolence was the most common adverse event, occurring in 10 percent of the lemborexant 10 mg group versus 1 percent of placebo recipients [2]. No adult data exist on tolerance development over periods longer than 12 months.

Why These Numbers Matter for Adolescent Prescribing

Clinicians who prescribe off-label to adolescents typically use these SUNRISE endpoints as the evidentiary anchor. The reasoning is that if a drug works mechanistically in adults with intact orexin circuitry, and if adolescent orexin circuitry is functionally comparable, then efficacy should translate. That reasoning is plausible. It is also unproven for ages 12 to 17 specifically.

Safety Profile and Adolescent-Specific Concerns

Somnolence and Next-Day Impairment

The 17-to-19-hour half-life of lemborexant means the drug is still measurably present the morning after a standard bedtime dose. In the SUNRISE-2 trial, next-morning driving performance was measured using a simulated road-tracking task [2]. Adults showed statistically significant impairment at 9 hours post-dose on 10 mg lemborexant compared with placebo [2]. Adolescents with early school start times, typically 7:30 a.m. Or earlier in the United States, may be at particular risk given the half-life overlap. The American Academy of Pediatrics has recommended that middle and high schools start no earlier than 8:30 a.m. Partly because of the mismatch between adolescent circadian phase delay and early school schedules [11].

Abuse and Dependence Potential

Lemborexant is a Schedule IV controlled substance under the Controlled Substances Act [7]. In preclinical studies, it showed lower abuse potential than zolpidem in self-administration models, but it retains scheduling because of residual CNS depressant properties [8]. Adolescents have higher rates of substance use experimentation than adults. The 2023 Monitoring the Future survey found that 5.0 percent of 12th-grade students reported nonmedical use of sedatives in the prior year [12]. Prescribing a Schedule IV sleep agent off-label in this demographic requires explicit discussion of diversion and misuse risk.

Suicidality and Mood

The FDA requires that all prescription sleep drugs carry labeling noting reports of complex sleep behaviors and worsening depression [7]. Adolescents have higher baseline rates of major depressive disorder than the general population. The 2023 National Survey on Drug Use and Health reported that 20.1 percent of adolescents aged 12 to 17 experienced at least one major depressive episode in the prior year [13]. Prescribers should screen for depression before initiating lemborexant and reassess at every follow-up visit.

Drug Interactions in Adolescent Patients

CYP3A4 inhibitors commonly used in teenagers include fluconazole (for vaginal candidiasis), clarithromycin (for respiratory infections), and certain HIV antiretrovirals used in adolescents with perinatally acquired HIV. Co-administration of a strong CYP3A4 inhibitor with lemborexant is contraindicated in the adult label and the same contraindication applies off-label [8]. Moderate CYP3A4 inhibitors require dose reduction to 5 mg maximum.

Approved and Evidence-Based Alternatives for Adolescent Insomnia

Before prescribing lemborexant off-label, clinicians should consider the alternatives with stronger pediatric evidence or regulatory standing.

Cognitive Behavioral Therapy for Insomnia

CBT-I is the first-line treatment for chronic insomnia in all age groups according to the American College of Physicians clinical practice guideline [14]. A 2021 meta-analysis published in JAMA Internal Medicine (k=87 trials) found that CBT-I produced a standardized mean difference of 1.01 for sleep onset latency reduction versus control conditions across adult and adolescent populations [14]. Adolescent-adapted CBT-I (CBT-IA) incorporating sleep hygiene, stimulus control, and circadian phase-shifting has demonstrated efficacy in randomized trials [15].

Melatonin and Ramelteon

Melatonin is not FDA-approved for any sleep indication but is widely used in pediatric populations. Doses of 0.5 to 3 mg taken 1 to 2 hours before desired sleep onset can advance circadian phase in adolescents with delayed sleep-wake phase disorder [16]. Ramelteon (Rozerem), an MT1/MT2 melatonin receptor agonist, is FDA-approved for adults and carries no scheduling designation, making it a lower-risk off-label choice in adolescents than Schedule IV agents [17].

Suvorexant

Suvorexant (Belsomra) is also a dual orexin receptor antagonist approved only for adults [18]. It shares the same mechanism as lemborexant with a longer half-life (approximately 12 hours, but with a range up to 15 hours). Neither DORA has adolescent trial data, so neither has an evidence advantage over the other in this age group.

Practical Prescribing Framework for Off-Label Lemborexant in Adolescents

When a clinician determines that off-label lemborexant is appropriate for an adolescent patient after exhausting CBT-I and lower-risk pharmacotherapy, the following framework reflects reasonable clinical practice based on adult labeling and general principles of pediatric pharmacology. This framework has not been validated in a prospective trial.

Step 1. Confirm diagnosis. Document chronic insomnia disorder per ICSD-3 criteria: subjective sleep difficulty three or more nights per week for three or more months with daytime functional impairment, not better explained by another sleep disorder such as obstructive sleep apnea or circadian rhythm disorder [4]. Polysomnography is not required for insomnia diagnosis but should be ordered if sleep-disordered breathing is suspected.

Step 2. Rule out contraindications. Obtain a full medication list to assess CYP3A4 interactions. Screen for narcolepsy symptoms (cataplexy, sleep paralysis, hypnagogic hallucinations), since orexin blockade could worsen narcolepsy type 2 or idiopathic hypersomnia. Assess for active suicidal ideation and current substance use.

Step 3. Start at 5 mg. Adult labeling recommends 5 mg as the starting dose for patients who may be sensitive to CNS depressants, including those on moderate CYP3A4 inhibitors [8]. Given the absence of adolescent PK data and the theoretical concern about body weight effects on exposure, 5 mg is the appropriate starting point for all adolescent patients regardless of weight.

Step 4. Counsel on next-day impairment. Discuss the half-life and the risk of morning drowsiness explicitly. Document that the patient and parent or guardian understand the drug may impair driving and school performance, particularly with early start times. The FDA's 2019 consumer update on sleep drug risks remains relevant for this counseling [7].

Step 5. Reassess at 4 weeks. Measure subjective sleep onset latency, total sleep time, and daytime functioning using a validated instrument such as the Pittsburgh Sleep Quality Index (PSQI) or the Adolescent Sleep-Wake Scale [19]. If no meaningful improvement occurs at 5 mg, consider titrating to 10 mg or discontinuing and re-evaluating the diagnosis.

Step 6. Plan for discontinuation. SUNRISE-2 showed no rebound insomnia with abrupt discontinuation in adults [2]. A taper is not pharmacologically required but may be preferred in adolescents with anxiety who are prone to anticipatory sleep worry. Document the planned treatment duration at initiation, since chronic adolescent sedative-hypnotic use carries uncharacterized developmental risks.

Informed Consent and Documentation Requirements

Off-label prescribing in adolescents requires thorough documentation. The prescriber should record the clinical rationale for selecting lemborexant over approved alternatives, the discussion of the absence of adolescent trial data, the specific risks communicated to the patient and parent or guardian, and the plan for monitoring and discontinuation. For patients under 18, both assent from the adolescent and informed consent from a parent or guardian are standard practice in most jurisdictions, though requirements vary by state.

The FDA's framework for off-label prescribing does not require a special consent form, but the agency notes that physicians have a professional responsibility to inform patients when a drug is being used beyond its labeled indication [7]. Medical malpractice risk in off-label pediatric prescribing is mitigated by documentation of evidence review, disclosure, and monitoring.

What Ongoing Research Exists?

As of mid-2025, ClinicalTrials.gov lists no completed or actively recruiting phase 2 or phase 3 trials of lemborexant specifically in the 12-to-17 age range [20]. A phase 1 open-label PK study in pediatric patients with insomnia associated with autism spectrum disorder (ages 2 to 17) was listed as completed by Eisai, but peer-reviewed results had not been published in indexed journals as of the article review date [20]. If those PK data are eventually published, they would represent the first primary-source pharmacokinetic data for lemborexant in the adolescent age group.

Clinicians interested in contributing to the evidence base should consider enrolling eligible adolescent patients in institutional review board-approved observational registries or, if available, industry-sponsored trials. The American Academy of Sleep Medicine maintains a registry for pediatric sleep disorders that accepts cases treated with off-label agents [4].

Comparison Table: Sleep Agents Used Off-Label in Adolescents

| Agent | Mechanism | Schedule | Adolescent RCT Data | Typical Starting Dose | |---|---|---|---|---| | Lemborexant | OX1R/OX2R antagonist | IV | None | 5 mg QHS | | Suvorexant | OX1R/OX2R antagonist | IV | None | 10 mg QHS | | Ramelteon | MT1/MT2 agonist | Not scheduled | Limited | 8 mg QHS | | Melatonin | MT1/MT2 agonist | OTC | Several small RCTs | 0.5 to 3 mg, 1-2h pre-sleep | | Trazodone | 5-HT2 antagonist/reuptake inhibitor | Not scheduled | Limited | 25 to 50 mg QHS | | Diphenhydramine | H1 antagonist | OTC | None for insomnia | Not recommended (tolerance in 3 days) |